Approval of Oral Medication for Diagnosing Adult Growth Hormone Deficiency
The Ministry of Food and Drug Safety announced on the 8th that it has approved the imported rare medicine 'Makrilen Granules' (active ingredient: Macimorelin Acetate) from Korea Pharmbio, used for diagnosing adult growth hormone deficiency.
Adult growth hormone deficiency is a condition in adults with insufficient growth hormone secretion, leading to abnormalities such as cardiovascular disease and fractures. It is known to occur in about 1 to 2 people per 10,000 population.
Until now, the insulin tolerance test has been used as the standard test to diagnose this condition. However, it causes hypoglycemia, requiring continuous monitoring, and is difficult to use in elderly patients or those with cardiovascular diseases.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
The Ministry of Food and Drug Safety expects Makrilen to complement these drawbacks of the insulin tolerance test. Makrilen is an oral medicine that stimulates growth hormone secretion by acting on the 'ghrelin receptor,' a growth hormone secretion-promoting receptor distributed in the pituitary gland and hypothalamus.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
